ABT Insider Buying & Government Contracts (2026)

ABT insider buying and selling over the past year

Over the past year ABBOTT LABORATORIES insiders filed 9 open-market Form 4 trades — 2 purchases worth $3.10M and 7 sales worth $688.4K — which makes them net buyers by $2.41M.

None of the 7 sales were flagged as Rule 10b5-1 plan trades, meaning each one was a discretionary decision at the time of filing. Activity clustered in 2026-03 (6 trades) and 2025-11 (1 trades); the latest filing in this window is dated 2026-03-02. The average open-market sale price was $118.99; the last close of $104.89 is 11.9% below that level, so sellers exited above the current price. The single largest trade was a purchase of 18,800 shares worth $2.01M on 2026-01-23. Since the most recent filing the stock has moved -8.1%, from $114.12. Insiders paid an average of $107.69 per share for their open-market purchases; against the last close of $104.89 that cost basis is under water at -2.6%.

Where ABT trades relative to its one-year range

ABBOTT LABORATORIES closed at $104.89 on 2026-10-16, inside a one-year range of $82.56 to $130.59. That puts the stock in the middle of its range, at 46.5% of the distance from low to high. Over one year the share price moved -17.8%, and over roughly three months +4.2%. Average daily volume over the last month was about 9,690,350 shares.

Across 137 companies in the same SEC industry group (SIC 28) with a full year of prices in Gemral Edge, the median one-year return was +12.0%. ABT is behind that median and beat 26% of that peer group on this measure.

Members of Congress who traded ABT

STOCK Act disclosures show 105 trades in ABT by 26 members of Congress over five years (42 purchases, 62 sales), most recently on 2026-09-18. The most active traders were Ro Khanna (D-CA), 44 trades; Josh Gottheimer (D-NJ), 7 trades; Gilbert Ray Cisneros, Jr. (D-CA), 6 trades; Richard McCormick (R-GA), 5 trades; Byron Donalds (R-FL), 4 trades.

By party the trades split 74 by Democrats, 31 by Republicans; by chamber, 102 from the House, 3 from the Senate.

ABBOTT LABORATORIES federal contract exposure

Federal procurement records resolve 5 prime award actions to ABBOTT LABORATORIES, worth $8.00M across 1 agencies. Department of Veterans Affairs accounts for 100.0% of that value ($8.00M), so revenue from this channel depends heavily on one buyer.

ABT lobbying disclosures

ABBOTT LABORATORIES appears in 12 Lobbying Disclosure Act filings between 2018 and 2018, with $2.01M in reported lobbying spend.

Compare ABT with indexed peers from the same industry group

These peers have full Gemral Edge dossiers and the closest one-year price move to ABT:

• IDXX one-year return -12.1%
• NVO one-year return -30.8%
• EBS one-year return -32.1%
• AZN one-year return -1.3%
• PPG one-year return +6.3%

Sources and method

Every figure above is computed from public filings stored in Gemral Edge, not estimated. Insider figures count only open-market purchases and sales reported on SEC Form 4; option exercises, grants and gifts are excluded because they do not reflect a decision to buy or sell at market prices.

• SEC EDGAR Form 4 (edge_insider_trades, codes P/S open-market only) — as of 2026-03-02
• edge_prices_eod (end-of-day close) — as of 2026-10-16
• House PTR / Senate eFD disclosures (edge_congress_trades) — as of 2026-09-18
• FPDS / USAspending (edge_contracts, tier-1 resolved) — as of 2026-10-09
• Senate LDA filings (edge_lobbying_filings)

ABT data questions

Are ABT insiders buying or selling stock?

Over the past year ABBOTT LABORATORIES insiders filed 9 open-market Form 4 trades — 2 purchases worth $3.10M and 7 sales worth $688.4K — which makes them net buyers by $2.41M.

What is the one-year price range for ABT?

Based on end-of-day closes through 2026-10-16, ABT traded between $82.56 and $130.59, last closing at $104.89.

Has any member of Congress traded ABT stock?

Yes. 26 members disclosed 105 trades in ABT over five years; the most recent disclosed trade date is 2026-09-18.